Lupus Trial, Recruiting NCT07424261 Sponsor: AstraZeneca Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT07424261
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older at the time of signing the consent form
  • You have been diagnosed with Systemic Lupus Erythematosus (SLE, a type of autoimmune disease)
  • Your doctor has prescribed you a medication called anifrolumab (given as an injection under the skin), following the approved guidelines for its use in Europe
  • Your doctor decided to prescribe this medication before and separately from this study — meaning the study did not influence your treatment decision
  • You are willing and able to take part in all study visits and procedures over the study period
  • You have signed and dated a consent form before joining the study

Who may not be able to join:

  • You have previously used anifrolumab at any point
  • You are currently being treated with other biologic medications (a certain type of advanced drug treatment)
  • You are already taking part in, or planning to join, another clinical trial that goes beyond your usual routine care
  • You currently have a severe, fast-worsening form of lupus affecting the kidneys (certain specific types), or severe and unstable lupus affecting the brain or mental health, that requires intensive treatment (confirm with trial site)
  • Your doctor feels that a current health condition — such as significant memory or thinking problems, severe unstable mental illness, or uncontrolled alcohol or substance use — would prevent you from completing questionnaires or attending visits regularly over 24 months
  • You are pregnant or breastfeeding at the time of joining the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
19 March 2026
Est. completion
31 August 2029

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Proportion and number of patients who fulfill criteria for definition of remission in SLE (DORIS remission)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov